Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model

International Journal of Cardiovascular Interventions

Volumn 5, Issue 3, 2003, Pages 166-171

  Huang, Yanming ^a   Liu, Xiaoshun ^a   Wang, Lan ^a   Verbeken, Eric ^a   Li, Shengqiao ^a   De Scheerder, Ivan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Angioplasty; Inflammation; Restenosis; Stents

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOMATERIAL; METHYLPREDNISOLONE; PHOSPHORYLCHOLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; EXPERIMENTAL MODEL; FEMALE; FOLLOW UP; IMPLANTATION; INFLAMMATION; MALE; MATERIAL COATING; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; THROMBOSIS PREVENTION;

EID: 0141427686     PISSN: 14628848     EISSN: None     Source Type: Journal    
DOI: 10.1080/14628840310017393     Document Type: Article

References (17)

1. Van der Giessen WJ, Lincoff AM, Schwartz RS et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996; 94: 1690-97.
2. De Scheerder IK, Wilczek KL, Verbeken EV et al. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 1995; 114: 105-14.
3. Campbell EJ, O'Byrne V, Stratford PW et al. Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer. ASAIO J 1994; 40: M853-M857.
4. Veil KR, Chronos NAF, Palmer SJ et al. Phosphorylcholine: a biocompatible coating for coronary angioplasty devices. Circulation 1995: 685 (abstr).
5. Whelan DM, van der Giessen WJ, Krabbendam SC et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83: 338-34.
6. Kuiper KK, Robinson KA, Chronos NA et al. Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries. Scand Cardiovasc J 1998; 32: 261-68.
7. De Scheerder I, Wang K, Wilczek KL et al. Local methylprednisolone inhibition of foreign body response to coated intracoronary stents. Coron Artery Dis 1996; 7: 161-66.
8. Schwartz RS, Huber KC, Murphy JG et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 19: 267-74.
9. Galli M, Bartorelli A, Bedogni F et al. Italian BiodivYsio open registry (BiodivYsio PC-coated stent): study of clinical outcomes of the implant of a PC-coated coronary stent. J Invas Cardiol 2000; 12: 452-58.
10. Zheng H, Barragan P, Corcos T et al. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J Invas Cardiol 1999; 11: 608-14.
11. De Scheerder I, Huang Y, Schacht E. New concepts for drug eluting stents. Sixth Local Drug Delivery Meeting and Cardiovascular Course on Radiation and Molecular Strategies, 27-29 January 2000, Geneva, Switzerland.
12. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanism of action and clinical consideration. Ann Intern Med 1976; 84: 304-15.
13. Voisard R, Seitzer U, Baur R et al. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int J Cardiol 1994; 43: 257-67.
14. Edelman ER, Rogers C. Pathobiologic responses to stenting. Am J Cardiol 1998; 81: 4E-6E.
15. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001; 103: 1718-20.
16. Parente L, Fitzgerald MF, Flower RJ et al. The effect of glucocorticoids on lyso-PAF formation in vitro and in vivo. Agents Actions 1986; 17: 312-13.
17. Kornowski R, Hong MK, Tio FO et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-30.